Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring

The Egyptian Heart Journal

Table 2 Comparing heart rate variability (HRV) time-domain and frequency-domain measures at baseline and after completion of treatment

Variable	Baseline (n = 50)	After completion of treatment (n = 50)	p value
HRV time-domain measures
SDNN, ms	121.70 ± 24.24	133.56 ± 50.79	0.122
SDANN, ms	111.99 ± 31.13	113.03 ± 79.76	0.913
RMSSD, ms	36.68 ± 19.49	105.06 ± 118.48	0.21
HRV triangular index	37.39 ± 16.69	27.21 ± 12.15	0.31
HRV frequency-domain measures
ULF power, ms²	11308 ± 4001.5	7270.4 ± 4551.4	0.092
VLF power, ms²	1566.5 ± 1454.4	1331.1 ± 865.41	0.876
LF power, ms²	1103.2 ± 1290.6	2584.1 ± 4392.2	0.225
HF power, ms²	709.28 ± 724.54	4323.2 ± 8251.2	0.165
LF/HF ratio	2.85 ± 3.62	1.39 ± 0.846	0.194

Continuous variables are expressed as mean and standard deviation
HRV means heart rate variability; SDNN means standard deviation of NN intervals; SDANN means standard deviation of the average NN intervals for each 5 min segment of a 24-h HRV recording; RMSSD means root mean square of successive RR interval differences; ULF power means absolute power of the ultra-low-frequency band (≤ 0.003 Hz); VLF power means absolute power of the very-low-frequency band (0.0033–0.04 Hz); LF power means absolute power of the low-frequency band (0.04–0.15 Hz); HF power means absolute power of the high-frequency band (0.15–0.4 Hz)